Tandem Diabetes Care Stock Performance
| TNDM Stock | USD 35.12 0.15 0.43% |
On a scale of 0 to 100, Tandem Diabetes holds a performance score of 12. The entity has a beta of 2.63, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Tandem Diabetes will likely underperform. Please check Tandem Diabetes' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Tandem Diabetes' existing price patterns will revert.
Risk-Adjusted Performance
12 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Tandem Diabetes Care are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating fundamental indicators, Tandem Diabetes displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.24) | Five Day Return 12.5 | Year To Date Return 23.14 | Ten Year Return (80.02) | All Time Return (81.89) |
Last Split Factor 1:10 | Dividend Date 2017-10-10 | Last Split Date 2017-10-10 |
1 | Tandem Diabetes Care, Inc. Reports Q4 Loss, Misses Revenue Estimates | 02/21/2024 |
2 | Disposition of 309 shares by Leal James of Tandem Diabetes subject to Rule 16b-3 | 02/27/2024 |
3 | Stonebridge Capital Advisors LLC Acquires Shares of 5,400 Tandem Diabetes Care, Inc. | 03/08/2024 |
4 | Disposition of 405 shares by Rick Carpenter of Tandem Diabetes subject to Rule 16b-3 | 03/15/2024 |
5 | IBD Rating Upgrades Tandem Diabetes Care Shows Improved Technical Strength | 03/21/2024 |
6 | Tandem Diabetes shares upgraded to buy, target raised to 37 | 03/25/2024 |
7 | At US30.10, Is Tandem Diabetes Care, Inc. Worth Looking At Closely | 03/26/2024 |
8 | Tandem Diabetes Care Shows Rising Price Performance With Jump To 85 RS Rating | 03/28/2024 |
9 | Tandem Diabetes Gains From Innovation Amid Macro Issues | 04/01/2024 |
10 | Should You Invest in Tandem Diabetes Care | 04/05/2024 |
11 | Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024 | 04/09/2024 |
12 | DexCom , MD Revolution Unite to Boost Diabetes Management | 04/15/2024 |
13 | Mirae Asset Global Investments Co. Ltd. Has 3.90 Million Stock Position in Tandem Diabetes Care, Inc. NASDAQ ... - Defense World | 04/17/2024 |
14 | Whats Driving Tandem Diabetes Care Incs Surprising 31 percent Stock Rally | 04/23/2024 |
| Begin Period Cash Flow | 172.5 M |
Tandem |
Tandem Diabetes Relative Risk vs. Return Landscape
If you would invest 2,299 in Tandem Diabetes Care on January 25, 2024 and sell it today you would earn a total of 1,198 from holding Tandem Diabetes Care or generate 52.11% return on investment over 90 days. Tandem Diabetes Care is currently generating 0.7897% in daily expected returns and assumes 5.047% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Tandem, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Tandem Diabetes Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Tandem Diabetes' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Tandem Diabetes Care, and traders can use it to determine the average amount a Tandem Diabetes' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1565
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TNDM | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.05 actual daily | 44 56% of assets are more volatile |
Expected Return
| 0.79 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.16 actual daily | 12 88% of assets perform better |
Based on monthly moving average Tandem Diabetes is performing at about 12% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Tandem Diabetes by adding it to a well-diversified portfolio.
Tandem Diabetes Fundamentals Growth
Tandem Stock prices reflect investors' perceptions of the future prospects and financial health of Tandem Diabetes, and Tandem Diabetes fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Tandem Stock performance.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.0963 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 2.25 B | ||||
| Shares Outstanding | 64.56 M | ||||
| Price To Earning | 494.25 X | ||||
| Price To Book | 6.90 X | ||||
| Price To Sales | 2.89 X | ||||
| Revenue | 747.72 M | ||||
| Gross Profit | 412.99 M | ||||
| EBITDA | (118.22 M) | ||||
| Net Income | (222.61 M) | ||||
| Cash And Equivalents | 608.73 M | ||||
| Cash Per Share | 9.47 X | ||||
| Total Debt | 415.67 M | ||||
| Debt To Equity | 1.00 % | ||||
| Current Ratio | 4.80 X | ||||
| Book Value Per Share | 4.78 X | ||||
| Cash Flow From Operations | (31.81 M) | ||||
| Earnings Per Share | (3.43) X | ||||
| Market Capitalization | 2.26 B | ||||
| Total Asset | 952.66 M | ||||
| Retained Earnings | (951.8 M) | ||||
| Working Capital | 552.73 M | ||||
| Current Asset | 106.98 M | ||||
| Current Liabilities | 26.52 M | ||||
About Tandem Diabetes Performance
To evaluate Tandem Diabetes Care Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Tandem Diabetes generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Tandem Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Tandem Diabetes Care market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Tandem's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 151.69 | 176.39 | |
| Return On Tangible Assets | (0.23) | (0.25) | |
| Return On Capital Employed | (0.31) | (0.29) | |
| Return On Assets | (0.23) | (0.25) | |
| Return On Equity | (0.71) | (0.67) |
Things to note about Tandem Diabetes Care performance evaluation
Checking the ongoing alerts about Tandem Diabetes for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Tandem Diabetes Care help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Tandem Diabetes Care is way too risky over 90 days horizon | |
| Tandem Diabetes Care appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 747.72 M. Net Loss for the year was (222.61 M) with profit before overhead, payroll, taxes, and interest of 412.99 M. | |
| Tandem Diabetes Care currently holds about 608.73 M in cash with (31.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.47. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Whats Driving Tandem Diabetes Care Incs Surprising 31 percent Stock Rally |
- Analyzing Tandem Diabetes' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Tandem Diabetes' stock is overvalued or undervalued compared to its peers.
- Examining Tandem Diabetes' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Tandem Diabetes' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Tandem Diabetes' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Tandem Diabetes' stock. These opinions can provide insight into Tandem Diabetes' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (3.43) | Revenue Per Share 11.509 | Quarterly Revenue Growth (0.11) | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.